

PARTICULARS TO APPEAR ON THE OUTER PACKAGE CARDBOARD BOX

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Prednicortone 5 mg tablets

2. STATEMENT OF ACTIVE SUBSTANCES

Each tablet contains:

Prednisolone 5 mg

3. PACKAGE SIZE

10 tablets
20 tablets
30 tablets
40 tablets
50 tablets
60 tablets
70 tablets
80 tablets
90 tablets
100 tablets
150 tablets
250 tablets
500 tablets

4. TARGET SPECIES

Dogs and cats.

5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oral use.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

Shelf life of the divided tablets: 4 days.

9. SPECIAL STORAGE PRECAUTIONS

Any unused tablet portion should be returned to the open blister space and inserted back into the carton.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Dechra Regulatory B.V.

14. MARKETING AUTHORISATION NUMBER

Vm 50406/4014

15. BATCH NUMBER

Lot {number}

MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS Alu/PVC/PE/PvDC blisters

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Prednicortone



2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Prednisolone 5 mg/tablet

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. {mm/yyyy}

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Prednicortone 5 mg tablets for dogs and cats

2. Composition

Each tablet contains:

Active substance:

Prednisolone 5 mg

Light brown with brown spots, round and convex flavoured tablet with a cross-shaped break line on one side.

Tablets can be divided into 2 or 4 equal parts.

3. Target species

Dogs and cats.



4. Indications for use

For the symptomatic treatment or as adjunct treatment of inflammatory and immune-mediated diseases in dogs and cats.

5. Contraindications

Do not use in animals suffering from viral or mycotic infections that are not controlled with an appropriate treatment.

Do not use in animals suffering from diabetes mellitus or hyperadrenocorticism.

Do not use in animals with osteoporosis.

Do not use in animals suffering from cardiac or renal dysfunction.

Do not use in animals suffering from corneal ulcers.

Do not use in animals with gastrointestinal ulceration.

Do not use in animals with burns.

Do not use concomitantly with attenuated live vaccine.

Do not use in the case of glaucoma.

Do not use during pregnancy (see also section: Special warnings; Pregnancy and lactation).

Do not use in cases of hypersensitivity to the active substance, to corticosteroids or to any of the excipients.

See also section: Interaction with other medicinal products and other forms of interaction.

6. Special warnings

Special warnings:

Corticoid administration is to induce an improvement in clinical signs rather than a cure. The treatment should be combined with treatment of the underlying disease and/or environmental control.

Special precautions for safe use in the target species:

In cases where a bacterial infection is present the veterinary medicinal product should be used in association with suitable antibacterial therapy.

Because of the pharmacological properties of prednisolone, special care should be taken when the veterinary medicinal product is used in animals with a weakened immune system.

Corticoids such as prednisolone, exacerbate proteinaceous catabolism. Consequently, the veterinary medicinal product should be carefully administered in old or malnourished animals.

Pharmacologically-active dose levels may lead to atrophy of the adrenal cortex, resulting in adrenal insufficiency. This may become apparent particularly after withdrawal of corticosteroid treatment. Adrenal insufficiency may be minimised by institution of alternate-day therapy if practical. The dosage should be reduced and withdrawn gradually to avoid precipitation of adrenal insufficiency (see section on: Amounts to be administered and administration route).

Corticoids such as prednisolone should be used with caution in patients with hypertension, epilepsy, previous steroid myopathy, in immunocompromised animals and in young animals as corticosteroids may induce a delayed growth.

The tablets are flavoured. In order to avoid any accidental ingestion, store tablets out of reach of the animals.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

Prednisolone or other corticosteroids may cause hypersensitivity (allergic reactions).

People with known hypersensitivity to prednisolone or other corticosteroids, or any of the excipients, should avoid contact with the veterinary medicinal product.

To avoid accidental ingestion, particularly by a child, unused part-tablets should be returned to the open blister space and inserted back into the carton.

In case of accidental ingestion, especially by a child, seek medical advice immediately and show the package leaflet or the label to the physician.

Corticosteroids can cause foetal malformations; therefore, it is recommended that pregnant women avoid contact with the veterinary medicinal product.

Immediately wash hands thoroughly after handling the tablets.

Pregnancy and lactation:

Do not use during pregnancy.

Studies in laboratory animals have shown that administration during early pregnancy may cause foetal abnormalities.

Administration during the later stages of pregnancy may cause abortion or early parturition. See also the section on contraindications.

Glucocorticoids are excreted in the milk and may result in growth impairment in suckling young animals.
Use during lactation only according to the benefit-risk assessment by the responsible veterinarian.

Interaction with other medicinal products and other forms of interaction:

Phenytoin, barbiturates, ephedrine and rifampicin, may accelerate the metabolic clearance of corticosteroids resulting in decreased blood levels and reduced physiological effect.

The concomitant use of this veterinary medicinal product with non-steroidal anti-inflammatory drugs may exacerbate gastrointestinal tract ulceration. Because corticosteroids can reduce the immunoresponse to vaccination, prednisolone should not be used in combination with vaccines or within two weeks after vaccination.

Administration of prednisolone may induce hypokalaemia and hence increase the risk of toxicity from cardiac glycosides. The risk of hypokalaemia may be increased if prednisolone is administered together with potassium depleting diuretics.

Overdose:

An overdose does not cause other adverse effects than those stated in the section on adverse reactions. An antidote is not known.

7. Adverse events

Dogs and cats:

Very common (>1 animal / 10 animals treated):	Cortisol suppression ¹ , elevated triglyceride ²
Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Excitation Pancreatitis Cushings disease ³ , Diabetes mellitus Hepatomegaly Elevated serum alkaline phosphatase (ALP) ⁴ , elevated liver enzymes, eosinopenia, neutrophilia ⁵ , lymphopenia, hypokalaemia ⁶ , low thyroxine (T4) Muscle weakness, muscle wasting Polyuria ⁷ Skin thinning, cutaneous calcinosis Polyphagia ⁷ , polydipsia ⁷
Undetermined frequency (cannot be estimated from the available data)	Gastrointestinal ulceration ⁸ Decreased aspartate transaminase (AST), decreased lactate dehydrogenase (LDH), hyperalbuminaemia, low tri-iodothyronine (T3), elevated parathyroid (PTH) concentration

	<p>Inhibition of longitudinal growth of bones, osteoporosis</p> <p>Delayed healing⁹, sodium and water retention⁶, alteration of fat, increased weight</p> <p>Immunosuppression¹⁰, weakened resistance to or exacerbation of existing infections¹⁰</p> <p>Adrenal insufficiency¹¹, adrenocortical atrophy¹¹</p>
--	--

¹ dose related, as a result of effective doses suppressing the hypothalamic-pituitary-adrenal axis.

² as part of possible iatrogenic hyperadrenocorticism (Cushings disease).

³ iatrogenic, involving significant alteration of fat, carbohydrate, protein and mineral metabolism.

⁴ could be related to enlargement of the liver (hepatomegaly) with increased serum hepatic enzymes.

⁵ increase of segmented neutrophils.

⁶ in long-term use.

⁷ after systemic administration and particularly during early stages of therapy.

⁸ may be exacerbated by steroids in animals given non-steroidal anti-inflammatory drugs and in animals with spinal cord trauma.

⁹ wound.

¹⁰ in the presence of viral infections, corticosteroids may worsen or hasten the progress of the disease.

¹¹ can arise following cessation of treatment and this may render the animal unable to deal adequately with stressful situations. Consideration should therefore be given to means of minimizing problems of adrenal insufficiency following the withdrawal of treatment.

Anti-inflammatory corticosteroids, such as prednisolone, are known to exert a wide range of side effects. Whilst single high doses are generally well tolerated, they may induce severe side-effects in long term use. Dosage in medium to long term use should therefore generally be kept to the minimum necessary to control symptoms. See also the section on Special Warnings: Pregnancy and lactation.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Oral use.

The dose and total duration of treatment is determined by the veterinarian per individual case depending on the severity of symptoms. The lowest effective dose must be used.

To ensure a correct dosage, body weight should be determined as accurately as possible.


Starting dose: 0.5 - 4 mg per kg bodyweight per day.

For longer term treatment: when after a period of daily dosing the desired effect has been achieved, the dose should be reduced until the lowest effective dose is reached. The reduction of the dose should be made by alternate day therapy and /or by halving the dose with intervals of 5-7 days until the lowest effective dose is reached.

9. Advice on correct administration

Dogs should be treated in the morning and cats in the evening on account of differences in day rhythm.

Tablets can be divided into equal 2 or 4 equal parts to ensure accurate dosing. Place the tablet on a flat surface, with its scored side facing up and the convex (rounded) side facing the surface.



Halves: press down with your thumbs on both sides of the tablet.

Quarters: press down with your thumb in the middle of the tablet.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Shelf life of the divided tablets: 4 days.

Any unused tablet portion should be returned to the open blister space and inserted back into the carton.

This veterinary medicinal product does not require any special temperature storage conditions.

Do not use this veterinary medicinal product after the expiry date which is stated on the label and the carton after Exp.

The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBERS AND PACK SIZES

Vm 50406/4014

Cardboard box of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 25 or 50 blisters of 10 tablets.

Not all pack sizes may be marketed.

15. PID link (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder

Dechra Regulatory B.V.

Handelsweg 25

5531 AE Bladel

The Netherlands

Manufacturer responsible for batch release:

Lelypharma B.V.
Zuiveringweg 42
8243 PZ Lelystad
The Netherlands


Genera d.d.
Svetonedeljska cesta 2
10 436 Rakov Potok
Croatia

Local representatives and contact details to report suspected adverse reactions:

Dechra Veterinary Products Limited
Sansaw Business Park
Hadnall
Shrewsbury
Shropshire
SY4 4AS
United Kingdom
Tel: +44 (0) 1939 211200

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.

17. Other information



Divisible tablet

POM-V

Gavin Hall
Approved: 23 July 2025